EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Clinical Evaluation of Drug–Drug Interactions With Aficamten

Neha Maharao, Donghong Xu iD, Punag Divanji, Tyrell J Simkins, Jianlin Li, Camelia Dumitrescu, Priyanka Solanki, Adrienne Griffith, Stephen B Heitner iD, Stuart Kupfer iD, Polina German, Justin D Lutz

Clinical and Translational Science · 2026-03 · 19 (3)

DOI: 10.1111/cts.70514 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, online erschienen am 05.03.2026. Verfasst von Neha Maharao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA. Hauptthemen laut MEDLINE: Drug Interactions, Pyrazoles. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aficamten is a next‐in‐class small molecule cardiac myosin inhibitor that was recently approved by the United States Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM). A comprehensive drug–drug interaction (DDI) evaluation of aficamten was achieved through two phase 1 studies in healthy participants. Aficamten as a victim of DDIs was studied using a moderate‐to‐strong P450 inducer (carbamazepine) and CYP inhibitors—itraconazole (strong CYP3A), paroxetine (strong CYP2D6), fluconazole (strong CYP2C19 and moderate 2C9 and 3A), and fluoxetine (strong CYP2D6 and 2C19). Aficamten's potential for P‐glycoprotein (P‐gp) inhibition was assessed using dabigatran etexilate (sensitive P‐gp substrate). Minor increases in aficamten exposure (area under the curve) were observed following treatment with itraconazole (26%), paroxetine (27%), and fluoxetine (32%) compared with aficamten alone. Treatment with carbamazepine decreased aficamten exposure by 50%. Concomitant administration of aficamten with fluconazole, a multi‐P450 inhibitor, resulted in a 278% increase in aficamten exposure. Taken together, results from these studies indicate that aficamten is primarily eliminated via CYP2C9‐mediated metabolism (fraction metabolized [fm] = 54%) with contributions from CYP2D6 (fm = 21%), CYP3A (fm = 21%), and minimal metabolism via CYP2C19 (fm = 3%). A small increase (26%–27%) in dabigatran exposure was observed in the presence of aficamten; indicative of weak inhibition of P‐gp. Aficamten was well tolerated, and adverse events were generally mild. In conclusion, aficamten is metabolized by multiple P450 enzymes, limiting its DDI liability. Only weak DDIs (< 2‐fold) are likely from strong inhibition of any one pathway, and only moderate (< 5‐fold) impact on aficamten exposure is expected with strong multi‐pathway inhibitors or inducers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug InteractionsPyrazolesFemaleHumansMaleCardiac MyosinsCardiomyopathy, HypertrophicCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9Cytochrome P-450 Enzyme InhibitorsFluconazoleFluoxetineItraconazoleParoxetine

Stichwörter der Autor:innen

aficamtencardiac myosin inhibitordrug–drug interactionheart failurehypertrophic cardiomyopathypharmacokinetics

Substanzen

aficamtenCardiac MyosinsCYP2C19 protein, humanCYP2C9 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9Cytochrome P-450 Enzyme InhibitorsFluconazoleFluoxetineItraconazole

Autor:innen und Institutionen

  • Department of Clinical Pharmacology, Cytokinetics, Incorporated, South San Francisco, California, USA.
  • Department of Clinical Research, Cytokinetics, Incorporated, South San Francisco, California, USA.
  • Department of Biostatistics, Cytokinetics, Incorporated, South San Francisco, California, USA.
  • Department of Drug Safety and Pharmacovigilance, Cytokinetics, Incorporated, South San Francisco, California, USA.

ORCID-Profile: Donghong Xu, Stephen B Heitner, Stuart Kupfer

Zitieren

APA

Maharao, N., Xu, D., Divanji, P., Simkins, T. J., Li, J., Dumitrescu, C., Solanki, P., Griffith, A., Heitner, S. B., Kupfer, S., German, P., & Lutz, J. D. (2026). Clinical Evaluation of Drug–Drug Interactions With Aficamten. Clinical and Translational Science, 19(3). https://doi.org/10.1111/cts.70514

Vancouver

Maharao N, Xu D, Divanji P, Simkins TJ, Li J, Dumitrescu C, et al. Clinical Evaluation of Drug–Drug Interactions With Aficamten. Clinical and Translational Science. 2026;19(3). doi:10.1111/cts.70514

BibTeX
@article{Maharao2026,
  author = {Maharao, Neha and Xu, Donghong and Divanji, Punag and Simkins, Tyrell J and Li, Jianlin and Dumitrescu, Camelia and Solanki, Priyanka and Griffith, Adrienne and Heitner, Stephen B and Kupfer, Stuart and German, Polina and Lutz, Justin D},
  title = {Clinical Evaluation of Drug–Drug Interactions With Aficamten},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {3},
  doi = {10.1111/cts.70514}
}
Kostenlos starten →